# Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin

> **NCT04549363** · PHASE3 · TERMINATED · sponsor: **GlaxoSmithKline** · enrollment: 16 (actual)

## Conditions studied

- Multiple Myeloma

## Interventions

- **DRUG:** Belantamab mafodotin

## Key facts

- **NCT ID:** NCT04549363
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-12-21
- **Primary completion:** 2022-11-21
- **Final completion:** 2022-11-21
- **Target enrollment:** 16 (ACTUAL)
- **Why stopped:** The study has been terminated for reasons pertaining to feasibility
- **Last updated:** 2023-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04549363

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04549363, "Characterization of Corneal Epithelial Changes in Participants Treated With Belantamab Mafodotin". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04549363. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*